Some interesting detective work by Carl V.

Why GlaxoSmithKline? Today NJOY announced that they are hiring Pinney Associates former home of FDAs tobacco chief, Mitch Zeller, among other players a consulting firm that is closely associated with Glaxo. It is difficult to imagine that happening without Glaxos explicit approval, and difficult to imagine NJOY making that choice among such firms unless the connection was intentional. Glaxo also has other advantages over their competitors, including being in the NRT space (along with J&J and others, of course) and having a near monopoly on asthma and COPD drugs, the medicines products that are most similar to e-cigarettes and that could yield some cross-technologies.
Is a Glaxo acquisition of NJOY in the works? | Anti-THR Lies and related topics